Applying biopharma rigor to the vast
therapeutic potential of the endocannabinoid system

Modulating the endocannabinoid system is among the most promising fields in the pharmaceutical industry. At Artelo Biosciences, we’re applying true biopharma discipline toward developing and commercializing a diverse portfolio of novel therapeutic candidates targeting the endocannabinoid system.

How we’re delivering on the promise of the endocannabinoid system (ECS)

Understanding the science

We believe a biopharma approach will lead to novel and high-impact therapeutics which harness the full potential of the ECS

A portfolio-based strategy

Our diverse set of programs are focused on a broad portfolio of assets with three distinct mechanisms to modulate the ECS

Our proven leadership team

We have decades of experience in biopharmaceutical development, commercialization, and ECS science